1. 丁健 中国 中国科学院 中国工程院院士 Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and..
2. George R. Stark 美国 Cleveland Clinic Foundation 1987美国科学院院士;2002美国医学院院士 The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage
3. 于金明 中国 山东第一医科大学 中国工程院院士 Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patient..
4. 邓泽元 中国 南昌大学 Non-oxidized and oxidized flaxseed orbitides differently induce HepG2 cell apoptosis: involvement of..
5. 周彩存 中国 同济大学 Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer
6. Rainer,Schobert 德国 University of Bayreuth Fluorinated and N-Acryloyl-Modified 3,5-Di[(E)-benzylidene]piperidin-4-one Curcuminoid..
7. 孙士勇 美国 Emory University ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via f..
8. Daniel S,Peeper 荷兰 Netherlands Cancer Institute TSC2 regulates tumor susceptibility to TRAIL-mediated T-cell killing by orchestrating mTOR signaling
9. Jose R,Conejo-Garcia 美国 University of South Florida Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves ..
10. Tyler J,Curiel 美国 University of Texas Health Science Center at San Antonio Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves ..
11. 耿美玉 中国 中国科学院 Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and..
12. 丁克 中国 暨南大学 Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and..
13. 符立梧 中国 中山大学 Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resista..
14. 孙士勇 美国 Emory University Therapeutic potential of the novel Bcl-2/Bcl-X-L dual inhibitor, APG1252, alone or in combination ag..
15. 王少萌 美国 University of Michigan Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung canc..
16. Suresh S,Ramalingam 美国 Emory University Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung canc..
17. 孙士勇 美国 Emory University Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung canc..
18. 杨志新 中国 台湾大学 Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TK..
19. Jaenne, Pasi A. 美国 Harvard University Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TK..
20. 孙士勇 美国 Emory University Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors